

TRETINOIN CREAM TRETINOIN GEL FOR TOPICAL USE ONLY

Description:

Tretinoin Cream and Tretinoin Gel are used for the topical treatment of acne vulgaris. Tretinoin Gel contains tretinoin (retinoic acid, vitamin A acid) in either of two strengths, 0.025% or 0.01% by weight, in a gel vehicle of butylated hydroxytoluene, hydroxypropyl cellulose and alcohol (denatured with *tert*-butyl alcohol and brucine sulfate) 90% w/w. Tretinoin Cream contains tretinoin in either of three strengths, 0.1%, 0.05%, or 0.025% by weight, in a hydrophilic cream vehicle of stearic acid, isopropyl myristate, polyoxyl 40 stearate, stearyl alcohol, xanthan gum, sorbic acid, butylated hydroxytoluene, and purified water. Chemically, tretinoin is all*-trans*-retinoic acid and has the following structure:



Clinical Pharmacology:

Although the exact mode of action of tretinoin is unknown, current evidence suggests that topical tretinoin decreases cohesiveness of follicular epithelial cells with decreased microcomedo formation. Additionally, tretinoin stimulates mitotic activity and increased turnover of follicular epithelial cells causing extrusion of the comedones.

Indications and Usage:

Tretinoin is indicated for topical application in the treatment of acne vulgaris. The safety and efficacy of the long-term use of this product in the treatment of other disorders have not been established.

Contraindications:

Use of the product should be discontinued if hypersensitivity to any of the ingredients is noted.

Precautions:

General:

If a reaction suggesting sensitivity or chemical irritation occurs, use of the medication should be discontinued. Exposure to sunlight, including sunlamps, should be minimized during the use of tretinoin, and patients with sunburn should be advised not to use the product until fully recovered because of heightened susceptibility to sunlight as a result of the use of tretinoin. Patients who may be required to

have considerable sun exposure due to occupation and those with inherent sensitivity to the sun should exercise particular caution. Use of sunscreen products and protective clothing over treated areas is recommended when exposure cannot be avoided. Weather extremes, such as wind or cold, also may be irritating to patients under treatment with tretinoin.

Tretinoin acne treatment should be kept away from the eyes, the mouth, angles of the nose, and mucous membranes. Topical use may induce severe local erythema and peeling at the site of application. If the degree of local irritation warrants, patients should be directed to use the medication less frequently, discontinue use temporarily, or discontinue use altogether. Tretinoin has been reported to cause severe irritation on eczematous skin and should be used with utmost caution in patients with this condition.

Drug Interactions:

Concomitant topical medication, medicated or abrasive soaps and cleansers, soaps and cosmetics that have a strong drying effect, and products with high concentrations of alcohol, astringents, spices or lime should be used with caution because of possible interaction with tretinoin. Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid with tretinoin. It also is advisable to "rest" a patient's skin until the effects of such preparations subside before use of tretinoin is begun.

Carcinogenesis:

Long-term animal studies to determine the carcinogenic potential of tretinoin have not been performed. Studies in hairless albino mice suggest that tretinoin may accelerate the tumorigenic potential of weakly carcinogenic light from a solar simulator. In other studies, when lightly pigmented hairless mice treated with tretinoin were exposed to carcinogenic doses of UVB light, the incidence and rate of development of skin tumors was reduced. Due to significantly different experimental conditions, no strict comparison of these disparate data is possible. Although the significance of these studies to man is not clear, patients should avoid or minimize exposure to sun.

Pregnancy:

<u>Oral</u> tretinoin has been shown to be teratogenic in rats when given in doses 1000 times the topical human dose. Oral tretinoin has been shown to be fetotoxic in rats when given in doses 500 times the topical human dose. <u>Topical</u> tretinoin has not been shown to be teratogenic in rats and rabbits when given in doses of 100 and 320 times the topical human dose, respectively (assuming a 50 kg adult applies 250 mg of 0.1% cream topically). However, at these topical doses, delayed ossification of a number of bones occurred in both species. These changes may be considered variants of normal development and are usually corrected after weaning. There are no adequate and well-controlled studies in pregnant women. Tretinoin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers:

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when tretinoin is administered to a nursing woman.

GELS ARE FLAMMABLE. Note: Keep away from heat and flame. Keep tube tightly closed.

Adverse Reactions:

The skin of certain sensitive individuals may become excessively red, edematous, blistered, or crusted. If these effects occur, the medication should either be discontinued until the integrity of the skin is restored, or the medication should be adjusted to a level the patient can tolerate. True contact allergy to topical tretinoin is rarely encountered. Temporary hyper- or hypopigmentation has been reported with repeated application of tretinoin. Some individuals have been reported to have heightened susceptibility to sunlight while under treatment with tretinoin. To date, all adverse effects of tretinoin have been

reversible upon discontinuance of therapy (see Dosage and Administration).

Overdosage:

If medication is applied excessively, no more rapid or better results will be obtained and marked redness, peeling, or discomfort may occur. Oral ingestion of the drug may lead to the same side effects as those associated with excessive oral intake of Vitamin A.

Dosage and Administration:

Tretinoin Cream or Tretinoin Gel should be applied once a day, before retiring, to the skin where acne lesions appear, using enough to cover the entire affected area lightly. Gel: Excessive application results in "pilling" of the gel, which minimizes the likelihood of over application by the patient.

Application may cause a transitory feeling of warmth or slight stinging. In cases where it has been necessary to temporarily discontinue therapy or to reduce the frequency of application, therapy may be resumed or frequency of application increased when the patients become able to tolerate the treatment.

Alterations of vehicle, drug concentration, or dose frequency should be closely monitored by careful observation of the clinical therapeutic response and skin tolerance.

During the early weeks of therapy, an *apparent* exacerbation of inflammatory lesions may occur. This is due to the action of the medication on deep, previously unseen lesions and should not be considered a reason to discontinue therapy.

Therapeutic results should be noticed after two to three weeks but more than six weeks of therapy may be required before definite beneficial effects are seen.

Once the acne lesions have responded satisfactorily, it may be possible to maintain the improvement with less frequent applications, or other dosage forms.

Patients treated with tretinoin acne treatment may use cosmetics, but the area to be treated should be cleansed thoroughly before the medication is applied. (see Precautions.)

How Supplied:

Tretinoin is supplied as:

Tretinoin Cream			Tretinoin Gel		
NDC Code	Strength	Quantity	NDC Code	Strength	Quantity
66530-253-20 66530-253-45	0.025% Cream 0.025% Cream	20 g 45 g	66530-256-15 66530-256-45	0.01% Gel 0.01% Gel	15 g 45 g
66530-254-20 66530-254-45	0.05% Cream 0.05% Cream	20 g 45 g	66530-257-15 66530-257-45	0.025% Gel 0.025% Gel	15 g 45 g
66530-255-20 66530-255-45	0.1% Cream 0.1% Cream	20 g 45 g			

Storage Conditions:

Tretinoin Gel, 0.025% and 0.01%: store below 86°F.

Tretinoin Cream, 0.1%, 0.05%, and 0.025%: store below 80°F.

Rx only

Manufactured for:

Spear Dermatology Products Randolph, NJ 07869 USA

By:

Valeant Pharmaceuticals International, Inc. Laval, Quebec H7L 4A8, Canada

Rev. 11/16 9539301 20000284B

PATIENT INSTRUCTIONS

TRETINOIN CREAM

TRETINOIN GEL

Acne Treatment

PATIENT INSTRUCTIONS

For Topical Use Only

IMPORTANT

Read Directions Carefully Before Using

THIS LEAFLET TELLS YOU ABOUT TRETINOIN ACNE TREATMENT AS PRESCRIBED BY YOUR PHYSICIAN. THIS PRODUCT IS TO BE USED ONLY ACCORDING TO YOUR DOCTOR'S INSTRUCTIONS, AND IT SHOULD NOT BE APPLIED TO OTHER AREAS OF THE BODY OR TO OTHER GROWTHS OR LESIONS. THE LONG-TERM SAFETY AND EFFECTIVENESS OF THIS PRODUCT IN OTHER DISORDERS HAVE NOT BEEN EVALUATED. IF YOU HAVE ANY QUESTIONS, BE SURE TO ASK YOUR DOCTOR.

WARNINGS AND PRECAUTIONS

The effects of the sun on your skin. As you know, overexposure to natural sunlight or the artificial sunlight of a sunlamp can cause sunburn. Overexposure to the sun over many years may cause premature aging of the skin and even skin cancer. The chance of these effects occurring will vary depending on skin type, the climate and the care taken to avoid over exposure to the sun. Therapy with tretinoin may make your skin more susceptible to sunburn and other adverse effects of the sun, so unprotected exposure to natural or artificial sunlight should be minimized.

Laboratory findings. When laboratory mice are exposed to artificial sunlight, they often develop skin tumors. These sunlight-induced tumors may appear more quickly and in greater number if the mouse is also topically treated with the active ingredient in Tretinoin Cream and Gel, tretinoin. In some studies, under different conditions, however, when mice treated with tretinoin were exposed to artificial sunlight, the incidence and rate of development of skin tumors was reduced. There is no evidence to date that tretinoin alone will cause the development of skin tumors in either laboratory animals or humans. However, investigations in this area are continuing.

Use caution in the sun. When outside, even on hazy days, areas treated with tretinoin should be protected. An effective sunscreen should be used <u>any time you are outside</u> (consult your physician for a recommendation of an SPF level which will provide you with the necessary high level of protection). For extended sun exposure, protective clothing, like a hat, should be worn. Do not use artificial sunlamps while you are using tretinoin. If you do become sunburned, stop your therapy with tretinoin until your skin has recovered.

Avoid excessive exposure to wind or cold. Extremes of climate tend to dry or burn normal skin. Skin treated with tretinoin may be more vulnerable to these extremes. Your physician can recommend ways to manage your acne treatment under such conditions.

Possible problems. The skin of certain sensitive individuals may become excessively red, swollen, blistered or crusted. If you are experiencing severe or persistent irritation, discontinue the use of tretinoin and consult your physician. There have been reports that, in some patients, areas treated with tretinoin developed a temporary increase or decrease in the amount of skin pigment (color) present. The pigment in these areas returned to normal either when the skin was allowed to adjust to tretinoin or therapy was discontinued.

Use other medication only on your physician's advice. Only your physician knows which other medications may be helpful during treatment and will recommend them to you if necessary. Follow the physician's instructions carefully. In addition, you should avoid preparations that may dry or irritate your skin. These preparations may include certain astringents, toiletries containing alcohol, spices or lime, or certain medicated soaps, shampoos and hair permanent solutions. Do not allow anyone else to use this medication.

Do not use other medications with tretinoin which are not recommended by your doctor. The medications you have used in the past might cause unnecessary redness or peeling.

If you are pregnant, think you are pregnant or are nursing an infant: No studies have been conducted in humans to establish the safety of tretinoin in pregnant women. If you are pregnant, think you are pregnant, or are nursing a baby, consult your physician before using this medication.

GELS ARE FLAMMABLE. Note: Keep away from heat and flame. Keep tube tightly closed.

AND WHILE YOU'RE ON TRETINOIN THERAPY

Use a mild, non-medicated soap. Avoid frequent washings and harsh scrubbing. Acne isn't caused by dirt, so no matter how hard you scrub, you can't wash it away. Washing too frequently or scrubbing too roughly may at times actually make your acne worse. Wash your skin gently with a mild, bland soap. Two or three times a day should be sufficient. Pat skin dry with a towel. Let the face dry 20 to 30 minutes before applying tretinoin. Remember, excessive irritation such as rubbing, too much washing, use of other medications not suggested by your physician, etc., may worsen your acne.

HOW TO USE TRETINOIN

To get the best results with tretinoin therapy, it is necessary to use it properly. Forget about the instructions given for other products and the advice of friends. Just stick to the special plan your doctor has laid out for you and be patient. Remember, when tretinoin is *used properly*, many users see improvement by 12 weeks. AGAIN, FOLLOW INSTRUCTIONS - BE PATIENT – DON'T START AND STOP THERAPY ON YOUR OWN - IF YOU HAVE QUESTIONS, ASK YOUR DOCTOR.

To help you use the medication correctly, keep these simple instructions in mind.



- Apply tretinoin once daily before bedtime, or as directed by your physician. Your physician may advise, especially if your skin is sensitive, that you start your therapy by applying tretinoin every other night. First, wash with a mild soap and dry your skin gently. WAIT 20 to 30 MINUTES BEFORE APPLYING MEDICATION; it is important for skin to be completely dry in order to minimize possible irritation.
- It is better not to use more than the amount suggested by your physician or to apply more frequently than instructed. Too much may irritate the skin, waste medication and won't give faster or better results.
- Keep the medication away from the corners of the nose, mouth, eyes and open wounds. *Spread away from these areas when applying.*
- *Cream*: Squeeze about a half inch or less of medication onto the fingertip. While that should be enough for your whole face, after you have some experience with the medication you may find you need slightly more or less to do the job. The medication should become invisible almost immediately. If it is still visible, you are using too much. Cover the affected area lightly with Tretinoin Cream by first dabbing it on your forehead, chin and both cheeks, then spreading it over the entire affected area. Smooth gently into the skin.
- *Gel*: Squeeze about a half inch or less of medication onto the fingertip. While that should be enough for your whole face, after you have some experience with the medication you may find you need slightly more or less to do the job. The medication should become invisible almost immediately. If it is still visible, or if dry flaking occurs from the gel **within a minute or so**, you are using too much. Cover the affected area lightly with Tretinoin Gel by first dabbing it on your forehead, chin and both cheeks, then spreading it over the entire affected area. Smooth gently into the skin.
- It is recommended that you apply a moisturizer or a moisturizer with sunscreen that will not

aggravate your acne (noncomedogenic) every morning after you wash.

WHAT TO EXPECT WITH YOUR NEW TREATMENT

Tretinoin works deep inside your skin and this takes time. You cannot make tretinoin work any faster by applying more than one dose each day, but an excess amount of tretinoin may irritate your skin. Be patient.

There may be some discomfort or peeling during the early days of treatment. Some patients also notice that their skin begins to take on a blush.

These reactions do not happen to everyone. If they do, it is just your skin adjusting to Tretinoin and this usually subsides within two to four weeks. These reactions can usually be minimized by following instructions carefully. Should the effects become excessively troublesome, consult your doctor.

BY THREE TO SIX WEEKS, some patients notice an appearance of new blemishes (papules and pustules). At this stage it is *important to continue* using tretinoin.

If tretinoin is going to have a beneficial effect for you, you should notice a continued improvement in your appearance after 6 to 12 weeks of therapy. Don't be discouraged if you see no immediate improvement. Don't stop treatment at the first signs of improvement.

Once your acne is under control you should continue regular application of tretinoin until your physician instructs otherwise.

IF YOU HAVE QUESTIONS

All questions of a medical nature should be taken up with your doctor.

Manufactured for:

Spear Dermatology Products Randolph, NJ 07869 USA

By:

Valeant Pharmaceuticals International, Inc. Laval, Quebec H7L 4A8, Canada

Rev. 11/16 9539301 20000284B

Principal Display Panel - Tretinoin Cream, 0.025% Carton

SPEAR DERMATOLOGY PRODUCTS

NDC 66530-253-45

Tretinoin Cream, 0.025%

For Topical Use Only Usual Dosage: See package insert. Store below 80°F.

WARNING: Keep out of reach of children.



Principal Display Panel - Tretinoin Cream, 0.05% Carton

SPEAR DERMATOLOGY PRODUCTS

NDC 66530-254-45

Tretinoin Cream, 0.05%

For Topical Use Only Usual Dosage: See package insert. Store below 80°F.

WARNING: Keep out of reach of children.



Principal Display Panel - Tretinoin Cream, 0.1% Carton

SPEAR DERMATOLOGY PRODUCTS

Tretinoin Cream, 0.1%

NDC 66530-255-46

For Topical Use Only Usual Dosage: See package insert. Store below 80°F. WARNING: Keep out of reach of children.



Principal Display Panel - Tretinoin Gel, 0.01% Carton

NDC 66530-256-45

SPEAR DERMATOLOGY PRODUCTS

Tretinoin Gel, 0.01%

For Topical Use Only. Usual Dosage: See package insert. Store below 86°F.

WARNING: Keep out of reach of children.

Rx only

Net Wt. 45 g



Principal Display Panel - Tretinoin Gel, 0.025% Carton


SPEAR DERMATOLOGY PRODUCTS

NDC 66530-257-45

Tretinoin Gel 0.025%

For Topical Use Only. Usual Dosage: See package insert. Store below 86°F.

WARNING: Keep out of reach of children.



TRETINOIN			
retinoin cream			
Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:66530-253
Route of Administration	TOPICAL		
Active Ingredient/Active I	Moiety		
Ir	ngredient Name	Basis of Strength	n Strength
TRETINO IN (UNII: 5688 UTC0 1R)	(TRETINOIN - UNII:5688UTC01R)	TRETINOIN	0.25 mg in 1 g
Inactive Ingredients			
	Ingredient Name		Strength
STEARIC ACID (UNII: 4ELV7Z65A	AP)		
ISOPROPYL MYRISTATE (UNII:	0RE8K4LNJS)		
POLYOXYL 40 STEARATE (UNI			

V A	NTHAN GUM (UNII:			
	, , , , , , , , , , , , , , , , , , ,	,		
so	RBIC ACID (UNII: X)45WJ989B)		
BU	TYLATED HYDRO X	XYTOLUENE (UNII: 1P9 D0 Z171K)		
WA	TER (UNII: 059QF0)	KO0R)		
Pa	ckaging			
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1 1	NDC:66530-253-20	1 in 1 CARTON	02/06/2014	06/18/2020
1		20 g in 1 TUBE; Type 0: Not a Combination Product		
2	NDC:66530-253-45	1 in 1 CARTON	02/06/2014	07/31/2020
2		45 g in 1 TUBE; Type 0: Not a Combination Product		
2				
2				
Z				
	autoding Tufe			
	arketing Info	ormation		
Μ	arketing Info		Marketing Start Date	Marketing End Date

TRETINOIN				
retinoin cream				
Product Information				
Product T ype	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:66	530-254
Route of Administration	TOPICAL			
Active Ingredient/Active	Moiety			
:	Ingredient Name	Basis of St	rength S	Strength
		TRETNON		
) (TRETINOIN - UNII:5688UTC01R)	TRETINOIN	0.5	mg in 1 g
		TRETINOIN		
Inactive Ingredients	Ingredient Name	IRETINOIN		mg in 1 g rength
Inactive Ingredients STEARIC ACID (UNII: 4ELV7Z65	Ingredient Name AP)	IRETINOIN		
Inactive Ingredients STEARIC ACID (UNII: 4ELV7Z65 ISOPROPYL MYRISTATE (UNII	Ingredient Name AP) : 0 RE8K4LNJS)	IRETINOIN		
Inactive Ingredients STEARIC ACID (UNII: 4ELV7Z65 ISOPROPYL MYRISTATE (UNII POLYOXYL 40 STEARATE (UN	Ingredient Name AP) : 0 RE8 K4LNJS) III: 13A4J4NH9 I)			
Inactive Ingredients STEARIC ACID (UNII: 4ELV7Z65 ISOPROPYL MYRISTATE (UNII POLYOXYL 40 STEARATE (UN STEARYL ALCOHOL (UNII: 2KH	Ingredient Name AP) : 0 RE8 K4LNJS) III: 13A4J4NH9 I) R89 I4H1Y)			
Inactive Ingredients STEARIC ACID (UNII: 4ELV7Z65 ISOPROPYL MYRISTATE (UNII POLYOXYL 40 STEARATE (UN STEARYL ALCOHOL (UNII: 2KH XANTHAN GUM (UNII: TTV12P4)	Ingredient Name AP) : 0 RE8 K4LNJS) III: 13A4J4NH9 I) R89 I4H1Y) NEE)			
Inactive Ingredients STEARIC ACID (UNII: 4ELV7Z65 ISOPROPYL MYRISTATE (UNII POLYOXYL 40 STEARATE (UN STEARYL ALCOHOL (UNII: 2KH XANTHAN GUM (UNII: TTV12P4) SORBIC ACID (UNII: X045WJ988	Ingredient Name AP) : 0 RE8 K4LNJS) III: 13A4J4NH9 I) R89 I4H1Y) NEE) 9B)			
Inactive Ingredients STEARIC ACID (UNII: 4ELV7Z65 ISOPROPYL MYRISTATE (UNII POLYOXYL 40 STEARATE (UN STEARYL ALCOHOL (UNII: 2KH XANTHAN GUM (UNII: TTV12P4) SORBIC ACID (UNII: X045WJ988	Ingredient Name AP) : 0 RE8 K4LNJS) III: 13A4J4NH9 I) R89 I4H1Y) NEE) 9B)			
Inactive Ingredients STEARIC ACID (UNII: 4ELV7Z65 ISOPROPYL MYRISTATE (UNII POLYOXYL 40 STEARATE (UNI STEARYL ALCOHOL (UNII: 2KH XANTHAN GUM (UNII: TTV12P4) SORBIC ACID (UNII: X045WJ988 BUTYLATED HYDROXYTOLUI	Ingredient Name AP) : 0 RE8 K4LNJS) III: 13A4J4NH9 I) R89 I4H1Y) NEE) 9B)			
Inactive Ingredients STEARIC ACID (UNII: 4ELV7Z65 ISOPROPYL MYRISTATE (UNII POLYOXYL 40 STEARATE (UNI STEARYL ALCOHOL (UNII: 2KH XANTHAN GUM (UNII: TTV12P4) SORBIC ACID (UNII: X045WJ988 BUTYLATED HYDROXYTOLUI	Ingredient Name AP) : 0 RE8 K4LNJS) III: 13A4J4NH9 I) R89 I4H1Y) NEE) 9B)			

#	Item Code]	Package Description	Marke	ting Start Date	Mark	eting End Date
1 N	DC:66530-254-20	1 in 1 CARTON		02/06/20) 14	07/24/2	020
1		20 g in 1 TUBE	; Type 0: Not a Combination Product				
2 N	DC:66530-254-45	1 in 1 CARTON		02/06/20	14	07/24/2	020
2		45 g in 1 TUBE	; Type 0: Not a Combination Product				
М	arketing Info	rmation					
	arketing Category		on Number or Monograph Citation	Mark	eting Start Date	Mark	keting End Date
NDA	A authorized generic	NDA017522		02/06/	2014	07/24/2	2020
	ETINOIN						
reti	ETINOIN noin cream oduct Informati	ion					
reti Pr	noin cream	ion	HUMAN PRESCRIPTION DRUG	Ite m C	Code (Source)	ND	DC:66530-255
reti Pr Pro	noin cream oduct Informat		HUMAN PRESCRIPTION DRUG TOPICAL	Ite m C	Code (Source)	ND	DC:66530-255
reti Pr Pro	noin cream oduct Informat oduct Type			Ite m C	Code (Source)	ND	DC:66530-255
reti Pr Pro Rot	noin cream oduct Informat oduct Type	ion	TOPICAL	Ite m C	Code (Source)	ND	DC:66530-255
reti Pr Pro Rot	noin cream oduct Informati oduct Type ute of Administrat	ion /Active Moi	TOPICAL	Ite m C	Code (Source) Basis of Stre		DC:66530-255 Strength

Inactive	Ingredients

Ingredient Name	Strength
STEARIC ACID (UNII: 4ELV7Z65AP)	
ISOPROPYL MYRISTATE (UNII: 0 RE8 K4LNJS)	
POLYOXYL 40 STEARATE (UNII: 13A4J4NH9I)	
STEARYL ALCOHOL (UNII: 2KR8914H1Y)	
XANTHAN GUM (UNII: TTV12P4NEE)	
SORBIC ACID (UNII: X045WJ989B)	
BUTYLATED HYDRO XYTOLUENE (UNII: 1P9D0Z171K)	
WATER (UNII: 059QF0KO0R)	

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:66530-255-20	1 in 1 CARTON	02/06/2014	06/27/2020
1		20 g in 1 TUBE; Type 0: Not a Combination Product		
2	NDC:66530-255-45	1 in 1 CARTON	02/06/2014	06/11/2020
2		45 g in 1 TUBE; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA authorized generic	NDA0 17340	02/06/2014	06/27/2020

TRETINOIN					
tretinoin gel					
Product Informati	on				
Product Type	HUMAN PRESCRIPTION DRUG	Ite m	Code (Source)	ND	C:66530-256
Route of Administrat	ion TOPICAL				
Active Ingredient/	Active Moiety				
	Ingredient Name		Basis of Stre	ngth	Strength
TRETINO IN (UNII: 5688	3UTC01R) (TRETINOIN - UNII:5688UTC01R)		TRETINOIN		0.1 mg in 1 g
т., т. 1 .					
Inactive Ingredier					
	Ingredient Name				Strength
	YTOLUENE (UNII: 1P9 D0 Z171K)				
ALCOHOL (UNII: 3K99					
	DL (UNII: MD83SFE959)				
	E PTAHYDRATE (UNII: 0900CDH328) ELLULOSE (1600000 WAMW) (UNII: RFW2ET6?	(10)			
HIDROAIPROPIL CE	LLOLOSE (1000000 WAMW) (UNII. RFW2E16.	1P)			
Packaging					
# Item Code	Package Description		eting Start Date		eting End Date
	1 in 1 CARTON	02/06/	2014	03/20/2	021
	15 g in 1 TUBE; Type 0: Not a Combination Production		2014	0.2/20/2	0.21
	1 in 1 CARTON	02/06/	2014	03/20/2	021
2	45 g in 1 TUBE; Type 0: Not a Combination Produ	2t			
Marketing Info	rmation				
Marketing Category	Application Number or Monograph Cita	tion Mar	keting Start Date	Mark	eting End Date
NDA authorized generic	NDA0 179 55	02/0	5/2014	03/20/2	2021
TRETINOIN					
tretinoin gel					

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:66530-257
Route of Administration	TOPICAL		

Active Ingretation	t/Active Moiety			
	Ingredient Name]	Basis of Strength	Strength
FRETINO IN (UNII: 568	38UTC01R) (TRETINOIN - UNII:5688UTC01R)	TR	ETINOIN	0.25 mg in 1 g
Inactive Ingredie	nte			
	Ingredient Name			Strength
BUTYLATED HYDRO	XYTOLUENE (UNII: 1P9 D0 Z171K)			Strength
ALCOHOL (UNII: 3K9)				
	HOL (UNII: MD83SFE959)			
	IEPTAHYDRATE (UNII: O900CDH328)			
	ELLULOSE (1600000 WAMW) (UNII: RFW2ET671))		
HYDROXYPROPYL C	ELLULOSE (1600000 WAMW) (UNII: RFW2ET671	")		
HYDROXYPROPYL C Packaging	ELLULOSE (1600000 WAMW) (UNII: RFW2ET6711 Package Description		ng Start Date Ma	arketing End Da
HYDROXYPROPYL C Packaging # Item Code			•	arketing End Da
HYDROXYPROPYL C Packaging J Item Code NDC:66530-257-15	Package Description	Marketin	•	Ū.
HYDROXYPROPYL C Packaging I Item Code NDC:66530-257-15	Package Description 1 in 1 CARTON	Marketin	05/	Ū.
HYDROXYPROPYL C Packaging	Package Description 1 in 1 CARTON 15 g in 1 TUBE; Type 0: Not a Combination Product	Marketin 02/06/2014	05/	17/2021
HYDROXYPROPYL C Packaging I Item Code 1 NDC:66530-257-15 1 NDC:66530-257-45	Package Description 1 in 1 CARTON 15 g in 1 TUBE; Type 0: Not a Combination Product 1 in 1 CARTON	Marketin 02/06/2014	05/	17/2021
HYDROXYPROPYL C Packaging I NDC:66530-257-15 I NDC:66530-257-45	Package Description 1 in 1 CARTON 15 g in 1 TUBE; Type 0: Not a Combination Product 1 in 1 CARTON	Marketin 02/06/2014	05/	17/2021
HYDROXYPROPYL C Exaging Item Code 1 NDC:66530-257-15 1 2 NDC:66530-257-45 2	Package Description 1 in 1 CARTON 15 g in 1 TUBE; Type 0: Not a Combination Product 1 in 1 CARTON 45 g in 1 TUBE; Type 0: Not a Combination Product	Marketin 02/06/2014	05/	17/2021
HYDROXYPROPYL C Comparison Image: Comparison	Package Description 1 in 1 CARTON 15 g in 1 TUBE; Type 0: Not a Combination Product 1 in 1 CARTON 45 g in 1 TUBE; Type 0: Not a Combination Product ormation	Marketin 02/06/2014 02/06/2014	05/	17/2021

Labeler - Spear Dermatology Products Inc (066551941)

Establishment

Name	Address	ID/FEI	Business Operations
Valeant Pharmaceuticals International, Inc		245141858	MANUFACTURE(66530-253, 66530-254, 66530-255, 66530-256, 66530-257)

Establishment						
Name	Address	ID/FEI	Business Operations			
Janssen Ortho LLC		084894661	MANUFACTURE(66530-254, 66530-254, 66530-255, 66530-256, 66530-257)			

Establishment

Name	Address	ID/FEI	Business Operations
Jubliant HollisterStier General Partnership		246762764	MANUFACTURE(66530-253, 66530-255, 66530-255, 66530-257)